CXCR4 and hematopoietic and lymphoid cell neoplasm: The most clinically advanced CXCR4-targeting radiopharmaceuticals are the [68Ga]Ga-PentixaFor/[177Lu]Lu-PentixaTher theranostic analogues, initially developed for CXCR4-targeted imaging and treatment in hematological cancers, and now tested in several solid tumours (Vag et al. 2016).